Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart

Abstract Activation of classical and lectin complement pathways contributes to several human diseases. Empasiprubart is a humanized recycling monoclonal antibody that inhibits both pathways by binding to the CCP2 domain of complement factor 2 (C2), an interaction that is dependent on both Ca2+ and p...

Full description

Saved in:
Bibliographic Details
Main Authors: Inge Van de Walle, Laura Bracke, Heidi Gytz Olesen, Tonke van Bragt, Stéphanie Cadour, Phillip De Decker, Giorgia Ciurlia, Erwin Pannecoucke, Emma K. Persson, Olivier Van de Steen, Xinghong Leng, Gregers Rom Andersen, Domenica Gandini, C. Erik Hack
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-62925-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-62925-1

Similar Items